Citadel Advisors
OTLK icon

Citadel Advisors’s Outlook Therapeutics OTLK Stock Holding History

Citadel Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.4K Sell
113,700
-7,600
-6% -$3.28K ﹤0.01% 12634
2025
Q4 		$192K Buy
121,300
+104,100
+605% +$166K ﹤0.01% 11078
2025
Q3 		$18.2K Buy
+17,200
New +$29.7K ﹤0.01% 12506
2025
Q2 		– Sell
-39,100
Closed -$47.7K – 14369
2025
Q1 		$47.7K Buy
39,100
+5,700
+17% +$9.99K ﹤0.01% 12363
2024
Q4 		$63.1K Sell
33,400
-41,000
-55% -$169K ﹤0.01% 12122
2024
Q3 		$397K Buy
+74,400
New +$544K ﹤0.01% 8732

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Citadel Advisors's OTLK Position: Q1 2025 in Review

Citadel Advisors sold out of Outlook Therapeutics (OTLK) in Q1 2025, closing a stake of 8,692 shares — an estimated $15.2K sold.

Citadel Advisors first reported a position in OTLK in Q4 2017 and held it in 13 quarters. The position peaked at $397K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q1 2025.

  • Citadel Advisors reported no remaining Outlook Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 8,692 Outlook Therapeutics shares in Q1 2025, an estimated $15.2K.
  • Citadel Advisors first reported a position in Outlook Therapeutics in Q4 2017 and held it in 13 quarters.
  • Citadel Advisors's Outlook Therapeutics position peaked at $397K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.